Cargando…

Androgen receptor functions in prostate cancer development and progression

The androgen receptor (AR) is critical for the normal development of prostate and for its differentiated functions. The consistent expression of AR in prostate cancer (PCa), and its continued activity in PCa that relapse after androgen deprivation therapy (castration-resistant prostate cancer (CRPC)...

Descripción completa

Detalles Bibliográficos
Autor principal:	Balk, Steven P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Invited Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104081/ https://www.ncbi.nlm.nih.gov/pubmed/24759584 http://dx.doi.org/10.4103/1008-682X.126396

Ejemplares similares

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Speckle-type POZ protein mutations interrupt tumor suppressor function of speckle-type POZ protein in prostate cancer by affecting androgen receptor degradation
por: Lai, John, et al.
Publicado: (2014)

Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo
por: Pestell, Richard G, et al.
Publicado: (2014)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Androgen receptor splice variants and polycystic ovary syndrome: cause or effect?
por: Walters, Kirsty A, et al.
Publicado: (2016)

Reduced fetal androgen exposure compromises Leydig cell function in adulthood
por: Teerds, Katja J, et al.
Publicado: (2015)

From bench to bedside: bipolar androgen therapy in a pilot clinical study
por: Zhang, Qing, et al.
Publicado: (2015)

Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2020)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Testosterone replacement therapy and the risk of prostate cancer
por: Warburton, Daniel, et al.
Publicado: (2015)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Prevention of erectile dysfunction after radiotherapy for prostate cancer
por: Faiena, Izak, et al.
Publicado: (2014)

Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014)

Long-term survival of participants in the prostate cancer prevention trial
por: Silberstein, Jonathan L, et al.
Publicado: (2014)

Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014)

Lipogenic metabolism: a viable target for prostate cancer treatment?
por: Liang, Mengmeng, et al.
Publicado: (2014)

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity
por: Mendonca, Janet, et al.
Publicado: (2015)

HOXB13 and other high penetrant genes for prostate cancer
por: Pilie, Patrick G, et al.
Publicado: (2016)

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial
por: Thompson, Ian M, et al.
Publicado: (2014)

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification
por: Chiang, Yan Ting, et al.
Publicado: (2014)

Tools to identify the men with prostate cancer most appropriate for active surveillance?
por: Getzenberg, Robert H
Publicado: (2014)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Robotic radical prostatectomy in high-risk prostate cancer: current perspectives
por: Canda, Abdullah Erdem, et al.
Publicado: (2015)

Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods
por: Moyad, Mark A
Publicado: (2015)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Androgens and prostate disease
por: Cooper, Lori A, et al.
Publicado: (2014)

Trading in your spindles for blebs: the amoeboid tumor cell phenotype in prostate cancer
por: Morley, Samantha, et al.
Publicado: (2014)

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer
por: Wilson, Elizabeth M
Publicado: (2014)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Relapse of prostate cancer from the viewpoint of total gland volume kinetics theory
por: Watanabe, Hiroki
Publicado: (2015)

Salvage brachytherapy for locally recurrent prostate cancer after external beam radiotherapy
por: Yamada, Yasuhiro, et al.
Publicado: (2015)

Does tadalafil prevent erectile dysfunction in patients undergoing radiation therapy for prostate cancer?
por: Incrocci, Luca
Publicado: (2014)

Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?
por: Lughezzani, Giovanni, et al.
Publicado: (2015)

Appraising the European randomized study of screening for prostate cancer: what do the results mean?
por: Ilic, Dragan
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kq9s5n14s0smsuo5o1c6foeutp